Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

idexx laboratories inc. - IDXX

IDXX

Close Chg Chg %
698.02 6.21 0.89%

Closed Market

704.23

+6.21 (0.89%)

Volume: 392.45K

Last Updated:

Nov 13, 2026, 4:00 PM EDT

Trade Now

Company Overview: idexx laboratories inc. - IDXX

IDXX Key Data

Open

$706.40

 Day Range

702.53 - 711.23

52 Week Range

500.61 - 769.98

 Market Cap

$55.35B

Shares Outstanding

78.79M

 Public Float

78.49M

Beta

1.55

 Rev. Per Employee

N/A

P/E Ratio

47.36

 EPS

$14.91

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

685.71K

  

IDXX Performance

1 Week
 
 4.17%
 
1 Month
 
 25.67%
 
3 Months
 
 27.82%
 
1 Year
 
 2.07%
 
5 Years
 
 12.11%
 

IDXX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About idexx laboratories inc. - IDXX

IDEXX Laboratories, Inc. engages in the development, manufacturing, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing industries. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

IDXX At a Glance

IDEXX Laboratories, Inc.
One IDEXX Drive
Westbrook, Maine 04092-2040
Phone 1-207-556-0300 Revenue 4.30B
Industry Medical Specialties Net Income 1.06B
Sector Health Technology 2025 Sales Growth 10.422%
Fiscal Year-end 12 / 2026 Employees 11,000
View SEC Filings

IDXX Valuation

P/E Current 47.356
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 51.739
Price to Sales Ratio 12.737
Price to Book Ratio 33.592
Price to Cash Flow Ratio 46.53
Enterprise Value to EBITDA 36.824
Enterprise Value to Sales 12.922
Total Debt to Enterprise Value 0.018

IDXX Efficiency

Revenue/Employee 391,245.636
Income Per Employee 96,314.909
Receivables Turnover 6.209
Total Asset Turnover 1.295

IDXX Liquidity

Current Ratio 1.167
Quick Ratio 0.838
Cash Ratio 0.157

IDXX Profitability

Gross Margin 61.816
Operating Margin 31.718
Pretax Margin 30.769
Net Margin 24.618
Return on Assets 31.891
Return on Equity 66.202
Return on Total Capital 41.042
Return on Invested Capital 50.16

IDXX Capital Structure

Total Debt to Total Equity 60.799
Total Debt to Total Capital 37.811
Total Debt to Total Assets 29.13
Long-Term Debt to Equity 29.65
Long-Term Debt to Total Capital 18.439
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Idexx Laboratories Inc. - IDXX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.37B 3.66B 3.90B 4.30B
Sales Growth
+4.73% +8.72% +6.46% +10.42%
Cost of Goods Sold (COGS) incl D&A
1.39B 1.47B 1.52B 1.64B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
111.90M 114.91M 129.94M 145.18M
Depreciation
96.90M 101.11M 112.84M 124.98M
Amortization of Intangibles
15.00M 13.80M 17.10M 20.20M
COGS Growth
+5.71% +6.18% +3.39% +7.79%
Gross Income
1.98B 2.19B 2.37B 2.66B
Gross Income Growth
+4.05% +10.51% +8.53% +12.11%
Gross Profit Margin
+58.76% +59.72% +60.88% +61.82%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.10B 1.09B 1.25B 1.30B
Research & Development
254.82M 190.95M 219.79M 251.21M
Other SG&A
849.55M 902.99M 1.03B 1.04B
SGA Growth
+15.67% -0.94% +13.89% +3.97%
Other Operating Expense
- - - (2.20M)
-
Unusual Expense
- (2.80M) (1.60M) (2.70M)
EBIT after Unusual Expense
879.23M 1.09B 1.13B 1.37B
Non Operating Income/Expense
23.40M 10.24M 17.18M (846.00K)
Non-Operating Interest Income
1.06M 5.63M 12.70M 3.01M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
42.66M 41.58M 36.07M 42.70M
Interest Expense Growth
+30.82% -2.52% -13.25% +18.36%
Gross Interest Expense
42.66M 41.58M 36.07M 42.70M
Interest Capitalized
- - - -
-
Pretax Income
859.97M 1.06B 1.11B 1.32B
Pretax Income Growth
-4.73% +23.40% +4.59% +19.31%
Pretax Margin
+25.54% +28.99% +28.48% +30.77%
Income Tax
180.88M 216.13M 221.96M 264.73M
Income Tax - Current - Domestic
180.63M 231.64M 205.15M 90.93M
Income Tax - Current - Foreign
35.14M 32.80M 41.00M 42.59M
Income Tax - Deferred - Domestic
(37.40M) (42.96M) (29.35M) 126.17M
Income Tax - Deferred - Foreign
2.52M (5.34M) 5.16M 5.04M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
679.09M 845.04M 887.87M 1.06B
Minority Interest Expense
- - - -
-
Net Income
679.09M 845.04M 887.87M 1.06B
Net Income Growth
-8.83% +24.44% +5.07% +19.33%
Net Margin Growth
+20.17% +23.08% +22.78% +24.62%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
679.09M 845.04M 887.87M 1.06B
Preferred Dividends
- - - -
-
Net Income Available to Common
679.09M 845.04M 887.87M 1.06B
EPS (Basic)
8.1208 10.1731 10.7663 13.173
EPS (Basic) Growth
-7.11% +25.27% +5.83% +22.35%
Basic Shares Outstanding
83.62M 83.07M 82.47M 80.43M
EPS (Diluted)
8.0271 10.0627 10.6656 13.0758
EPS (Diluted) Growth
-6.70% +25.36% +5.99% +22.60%
Diluted Shares Outstanding
84.60M 83.98M 83.25M 81.03M
EBITDA
988.33M 1.21B 1.26B 1.51B
EBITDA Growth
-6.14% +22.17% +4.11% +20.14%
EBITDA Margin
+29.35% +32.98% +32.25% +35.09%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 741.75
Number of Ratings 17 Current Quarters Estimate 3.339
FY Report Date 12 / 2026 Current Year's Estimate 14.914
Last Quarter’s Earnings 4.01 Median PE on CY Estimate N/A
Year Ago Earnings 13.08 Next Fiscal Year Estimate 16.844
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 10 13 13
Mean Estimate 3.34 3.91 14.91 16.84
High Estimates 3.51 4.07 15.19 17.15
Low Estimate 3.26 3.47 13.52 16.47
Coefficient of Variance 2.16 4.56 2.98 1.12

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 8
OVERWEIGHT 1 1 1
HOLD 5 6 7
UNDERWEIGHT 0 1 1
SELL 1 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Idexx Laboratories Inc. - IDXX

Date Name Shares Transaction Value
Nov 13, 2026 George J. Fennell Executive Vice President 11,139 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $141.6 per share 1,577,282.40
Nov 13, 2026 George J. Fennell Executive Vice President 11,699 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $178.26 per share 2,085,463.74
Nov 13, 2026 George J. Fennell Executive Vice President 12,182 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $206.94 per share 2,520,943.08
Nov 13, 2026 George J. Fennell Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 13, 2026 George J. Fennell Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 13, 2026 George J. Fennell Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 84,909 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $710.12 per share 60,295,579.08
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 90,390 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $705.59 per share 63,778,280.10
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 90,630 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $703.45 per share 63,753,673.50
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 94,580 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $702.21 per share 66,415,021.80
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 96,716 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $701.36 per share 67,832,733.76
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 101,256 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $700.32 per share 70,911,601.92
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 102,923 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $699.33 per share 71,977,141.59
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 106,998 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $698.26 per share 74,712,423.48
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 108,943 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $178.26 per share 19,420,179.18
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 89,550 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $707 per share 63,311,850.00
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 86,410 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $709 per share 61,264,690.00
Nov 6, 2026 Daniel M. Junius Director 2,861 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $705.78 per share 2,019,236.58
Nov 6, 2026 Jonathan J. Mazelsky Executive Chair of the Board; Director 87,710 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $707.84 per share 62,084,646.40
Nov 6, 2026 Daniel M. Junius Director 2,361 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $701.68 per share 1,656,666.48

Idexx Laboratories Inc. in the News